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 Proceedings 
diffraction of sound waves as they travel around the head can com-
promise the ability to understand speech in noisy environments 
[Taylor, 2010].
 A range of hearing-assistive devices have been developed to ad-
dress some of the functional impairments caused by SSD [Bishop 
and Eloy, 2010]. Devices which re-route sounds arriving on the 
side of the impaired ear to the non-impaired ear can help overcome 
the head shadow. CROS (contralateral routing of signals) can im-
prove speech perception in noise when the signal-to-noise ratio is 
more favourable at the impaired ear than the non-impaired ear. 
This effect has been observed regardless of whether the re-routing 
is achieved through air or bone conduction [Baguley et al., 2006]. 
Useful aspects of binaural hearing may also be restored through 
cochlear implants (CIs), which have the capacity to support better-
ear listening and to provide access to interaural intensity cues. Al-
though binaural hearing following cochlear implantation in SSD 
requires the listener to integrate electric and acoustic information, 
studies have demonstrated that implantation can improve localisa-
tion and speech understanding in noise [Kamal et al., 2012].
 Despite having access to an unimpaired or minimally impaired 
ear, individuals with SSD report substantial difficulties with listen-
ing in many everyday situations and can report a level of psycho-
logical distress that may appear disproportionate to their level of 
residual acoustic hearing [McLeod et al., 2008]. Therefore, when 
evaluating the benefits of hearing-assistive devices for SSD, it is 
relevant to use outcome measures that can assess the impact on a 
patient’s overall health and well-being, or health-related quality of 
life (HRQoL). Instruments for measuring HRQoL can be classified 
as generic or disease specific. These approaches differ in whether 
they measure the impact on dimensions of health chosen to be rel-
evant to a wide range of health conditions or to be relevant to a 
particular disease. A systematic review of the literature was con-
ducted to establish the extent to which current hearing-assistive 
devices can have an impact on HRQoL in adults with SSD, wheth-
er the size of that impact differs between devices, and whether im-
pact has been demonstrated using both generic and disease-specif-
ic instruments.
 Methods 
 This review was conducted according to published recommen-
dations for identifying, grading, synthesizing and reporting evi-
dence from studies of health interventions [Centre for Reviews and 
Dissemination, 2009; Higgins and Green, 2009; Moher et al., 2009]. 
The criteria for inclusion, quality assessment, and meta-analysis 
were defined prospectively. Articles were identified by executing 
an electronic search of MEDLINE, EMBASE, PubMed, DARE, and 
Cochrane databases on 26th February 2014. No restrictions were 
imposed on language and the search included articles published 
from 1946 onwards. The search strategy requested articles whose 
title and/or abstract included: (a) at least one term relating to SSD 
(‘unilateral’, ‘single-sided’, ‘hearing loss’, ‘deafness’) or that were 
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 Abstract 
 Unilateral severe-to-profound hearing loss, or single-sided deafness 
(SSD), impairs listening abilities supported by the use of two ears, 
including speech perception in background noise and sound locali-
sation. Hearing-assistive devices can aid listening by re-routing 
sounds from the impaired to the non-impaired ear or by restoring 
input to the impaired ear. A systematic review of the literature ex-
amined the impact of hearing-assistive devices on the health-relat-
ed quality of life (HRQoL) of adults with SSD as measured using ge-
neric and disease-specific instruments. A majority of studies used 
observational designs, and the quality of the evidence was low to 
moderate. Only two studies used generic instruments. A mixed-ef-
fect meta-analysis of disease-specific measures suggested that hear-
ing-assistive devices have a small-to-medium impact on HRQoL. The 
Speech, Spatial and Qualities of Hearing Scale and the Health Utili-
ties Index Mark 3 (HUI3) were identified as instruments that are sen-
sitive to device-related changes in disease-specific and generic 
HRQoL, respectively.  © 2015 S. Karger AG, Basel 
 Introduction 
 A severe-to-profound hearing loss in one ear only, or single-
sided deafness (SSD), can have a measurable and detrimental im-
pact on many aspects of hearing [Douglas et al., 2007]. With only 
one functional ear, the binaural cues of interaural time and inten-
sity that underpin sound localisation are absent or distorted. Hear-
ing with one ear only also means that sounds that are located to-
wards the impaired ear are attenuated when arriving at the non-
impaired ear. This attenuation, or head shadow, caused by the 
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assigned the Medical Subject Heading term ‘hearing loss, unilat-
eral’ and (b) at least one term relating to devices (‘implant * ’, ‘de-
vice * ’, ‘prosthes * ’, ‘instrument * ’, ‘hearing aid * ’) or were assigned 
related Medical Subject Heading terms (‘bone conduction’, ‘hear-
ing aids’, ‘cochlear implants’, ‘auditory brain stem implants’, ‘den-
tal implants’, ‘ossicular prosthesis’).
 The criteria for inclusion in the review were specified in terms 
of PICOS (Participants, Interventions, Comparators, Outcomes 
and Study Design). The participants were adults with unilateral 
severe-to-profound sensorineural hearing loss defined as (1) a 
pure-tone average >70 dB HL in one ear with an air-bone gap  ≤ 10 
dB and (2) a pure-tone average  ≤ 30 dB HL in the other ear. The 
interventions were any hearing-assistive device, including, but not 
limited to, air (ACDs) or bone conduction devices (BCDs), CROS 
and CIs. The comparators were placebo devices or no treatment 
(unaided). Eligible outcomes included validated generic and dis-
ease-specific instruments for measuring changes in HRQoL. No 
restrictions were placed on the study design. Articles were permit-
ted to include multiple populations, but outcomes for the eligible 
population had to be reported separately.
 Titles and abstracts were retrieved and independently as-
sessed against the PICOS criteria by two of the authors. At this 
stage, articles were excluded only if both reviewers agreed that 
the criteria had not been met. The full text of the remaining ar-
ticles was retrieved and a secondary assessment was performed 
independently by the same two authors. Disagreements about 
whether an article satisfied the criteria were resolved by consen-
sus. Articles included in the review were subjected to a quality 
assessment. Two authors independently assessed whether each 
article indicated that (a) the allocation to group/intervention was 
randomised; (b) allocation was concealed; (c) ethical approval 
had been obtained; (d) data collection was prospective; (e) inclu-
sion and exclusion criteria were defined; (f) a power calculation 
was conducted; (g) a control group was included; (h) missing 
data were declared, and (i) sources of funding were reported. 
Each study was assigned an evidence level [Centre for Evidence-
Based Medicine, 2009] and disagreements between reviewers 
that arose in conducting the quality assessment were resolved by 
consensus.
 Data on eligible outcomes were extracted independently by two 
authors. Discrepancies in the data extracted that had been tran-
scribed from the text of an article were resolved by a third author. 
Where data had to be extracted from figures or illustrations, the 
average of the values estimated by the two authors was used. Efforts 
were made to contact authors where published data provided in-
sufficient information to calculate effect sizes. All effect sizes were 
calculated as standardised mean differences (SMDs) in which the 
mean difference between aided and unaided conditions was stan-
dardised by dividing it by the standard deviation of the differences 
(within-subject effects from repeated-measure designs) [Gibbons 
et al., 1993] or by the pooled standard deviation (between-group 
comparisons) [Hedges, 1981]. For between-group comparisons, 
effect sizes were categorised as small, medium or large if their val-
ue exceeded 0.2, 0.5 and 0.8, respectively [Cohen, 1988]. Bar-
cikowski and Robey [1985] suggested that equivalent thresholds 
for within-subject effects could be obtained by dividing these val-
ues by where  ρ is the correlation between scores before and 
after intervention. The resulting thresholds for within-subject ef-
fects were 0.3, 0.8 and 1.2 based on an average pre-post correlation 
of 0.56.
 For studies that adopted a repeated-measure (pre-post) design, 
an effect size was calculated if the means and standard deviations 
for the conditions before and after intervention were reported 
along with the correlation between the two measures. Effect sizes 
could also be derived from the mean and standard deviation of the 
pre-post differences, if reported. Where standard deviations or 
correlations were not reported, they were imputed from other ob-
servational studies that used the same outcome measure and inter-
vention. An average effect size was calculated where an article re-
ported outcomes at multiple time points after intervention. For 
studies that compared two groups, effect sizes were calculated from 
the means and standard deviations within each group. If required, 
effect sizes were also calculated from the values of test statistics or 
their probability values if the methodology was reported in suffi-
cient detail. Comparisons between effect sizes and a mixed-effect 
meta-analysis were conducted using the metafor package for the R 
statistical software [Viechtbauer, 2010].
 Results 
 Of the 334 articles retrieved from the electronic databases, 34 
articles were unanimously excluded based on titles and abstracts 
alone, and full texts were retrieved for the remaining 300 articles. 
Twenty-four articles were deemed to have met the inclusion crite-
ria and were included in the review ( table 1 ). A further 20 articles 
had satisfied the PICOS criteria but were excluded because data 
from adults with SSD were not reported separately from other pop-
ulations. Two articles reported outcomes from the same group of 
patients but after different durations of follow-up [Arndt et al., 
2011a, b].
 The majority of studies were non-experimental pre-post obser-
vational studies in which participants acted as their own controls 
(level of evidence 4). Two studies included control groups where 
the allocation to groups was not at random (level of evidence 3b) 
[Gluth et al., 2010; House et al., 2010] and one study used randomi-
sation to determine the order in which participants used two hear-
ing-assistive devices (level of evidence 1b) [Moore and Popelka, 
2013]. However, participants acted as their own controls when 
comparing HRQoL in the aided and unaided conditions in all but 
one study [House et al., 2010]. The results of the quality assessment 
are listed in  table 1 . While the majority of studies were prospective, 
several studies did not clearly specify inclusion/exclusion criteria 
or declare whether there were any missing data and, if so, how it 
was handled. Many studies did not state whether ethical approval 
was required or obtained, and did not declare sources of funding. 
Only one study reported conducting a power calculation.
 Two studies reported changes in HRQoL measured using ge-
neric instruments. Newman et al. [2008] reported outcomes before 
and after BCD use in terms of scores on the 36-item Short-Form 
Health Survey (SF-36) [Ware and Sherbourne, 1992]. The SF-36 
includes questions about impairments to eight health dimensions, 
including physical function, social function and mental health. 
However, estimates of variability were not reported, so effect sizes 
could not be calculated. Arndt et al. [2011a] measured the HRQoL 
of 11 adults with SSD using the Health Utilities Index Mark 3 
(HUI3) [Feeny et al., 1995]. The HUI3 was administered before 
any intervention, after 3-week trials of an ACD and a BCD worn 
on a headband, and 6 months after CI surgery. The HUI3 classifies 
the degree of impairment on eight health dimensions, including 
hearing and speech. The HUI3 can be used to derive a utility value 
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which expresses the health state of the respondent on a scale from 
0 to 1 based on the preferences of a random sample of the Cana-
dian public [Furlong et al., 1998]. Effect sizes for both CROS de-
vices had 95% confidence intervals (CIs) that embraced zero, with 
a smaller effect observed after ACD use (mean 0.26, 95% CI –0.37 
to 0.89) than after BCD use (mean 0.46, 95% CI –0.16 to 1.1). CI 
was associated with the largest-observed effect size of 0.69 (95% CI 
0.03–1.35). Although this result would be considered a medium 
effect size according to the thresholds proposed by Cohen [1988], 
it was classified as a small effect once the correlation between val-
ues before and after intervention was taken into account [Bar-
cikowski and Robey, 1985].
 All studies included disease-specific measures of HRQoL. The 
most frequently adopted measure was the Abbreviated Profile of 
Hearing Aid Benefit (APHAB, 15 studies). The APHAB includes 
four subscales: background noise (BN), reverberation (RV), ease 
of communication (EC) and aversion to sounds (AV) [Cox and 
Alexander, 1995]. Ten studies included the Speech, Spatial and 
Qualities of Hearing Scale (SSQ) [Gatehouse and Noble, 2004] and 
three studies included the Glasgow Hearing Aid Benefit Profile 
(GHABP) [Gatehouse, 1999]. Individual studies also included the 
Glasgow Benefit Inventory [Robinson et al., 1996], the Spatial 
Hearing Questionnaire (SHQ) [Tyler et al., 2009] and the Hearing 
Handicap Inventory for Adults (HHIA) [Newman et al., 1990]. 
The studies evaluated the impact of ACD, BCD and CI on HRQoL. 
Bone conduction interventions included devices mounted on head 
bands, on ossio-integrated abutments and on dental fixtures. 
However, as the objective of this review was to examine the impact 
of general device classes on HRQoL, effect sizes were grouped ac-
cording to whether the intervention was an ACD, BCD or CI.
 Effect sizes associated with the use of an ACD were derived 
from APHAB and SSQ scores ( fig.  1 ). Mean effect sizes ranged 
from –0.69 to 1.00 with the 95% CIs embracing zero for a majority 
of the effects. Negative effects were found for the AV subscale of 
the APHAB and the sections of the SSQ that dealt with speech and 
the quality of sounds. The largest positive effects were found for 
the BN and RV subscales of the APHAB and the spatial section of 
the SSQ. A similar pattern of effects was found for BCD use ( fig. 2 ), 
for which studies reported negative effects on HRQoL related to 
sound aversion and quality, and positive effects related to RV, BN, 
spatial listening and speech perception. Over half of the observed 
effects of BCD use had 95% CIs that did not embrace zero. Effect 
sizes for CIs were derived exclusively from SSQ data ( fig. 3 ). All 
but two CI effects had 95% CIs that did not embrace zero, and ef-
fect sizes ranged from 0.22 to 4.54.
 Estimated mean effect sizes for each category of hearing-as-
sistive device were derived from a mixed-effect meta-analysis
of disease-specific HRQoL data. The mean effect size obtained
using disease-specific instruments was influenced by device type 
[QM(2) = 12.93, p < 0.01]. All three devices had a statistically sig-
nificant impact on HRQoL, with the smallest effect found for ACD 
(mean 0.26, 95% CI 0.05–0.46), a larger effect for BCD (mean 0.55, 
 Table 1.  Characteristics of studies included in the review
First author, year n (SSD) Intervention(s) HRQoL
outcomes
Controls Grade  Quality assessment
 1 2 3 4 5 6 7 8 9
Arndt, 2011a, b 11 CI, BCD, ACD SSQ, HUI3 Own 4 – – + + + – – ? –
Barbara, 2010 7 BCD GBI Own 4 – – – + – – – + –
Bosman, 2003 9 BCD, ACD APHAB Own 4 – – – + – – – ? –
Desmet, 2012 10 BCD APHAB, SHQ Own 4 – – + + – – – ? –
Dumper, 2009 15 BCD APHAB, SSQ Own 4 – – – + + – – ? –
Firszt, 2012 3 CI SSQ Own 4 – – + + + – – + +
Gluth, 2010 56 BCD APHAB, GHABP SSD 3b – – + + + – – + –
Hassepass, 2013 2 CI SSQ Own 4 – – + + – – – + –
Hol, 2010 10 BCD, ACD APHAB, SSQ Own 4 – – – + – – – + –
House, 2010 129 BCD SSQ, APHAB SSD 3b – – – ? – – + + +
Lin, 2006 23 BCD, ACD APHAB Own 4 – – + + – – – + +
Moore, 2013 9 BCD APHAB SSD 1b2 + – – + + – + ? +
Murray, 2011 22 BCD APHAB Own 4 – – – + + – – ? +
Newman, 2008 10 BCD APHAB, HHIA1, SF-361 Own 4 – – + + – – – ? +
Niparko, 2003 10 BCD, ACD APHAB, GHABP Own 4 – – + + + – – ? –
Oeding, 2010 16 BCD APHAB Own 4 – – + + + + – ? +
Pai, 2012 25 BCD SSQ Own 4 – – – + + – – ? –
Saliba, 2011 21 BCD APHAB Own 4 – – + + + – – ? –
Tavora-Vieira, 2013a 5 CI SSQ Own 4 – – + + + – – ? –
Tavora-Vieira, 2013b 9 CI SSQ Own 4 – – + + + – – ? +
Vermeire, 2009 20 CI SSQ Own 4 – – + + – – – ? –
Wazen, 2003 18 BCD, ACD APHAB Own 4 – – – + – – – ? +
Yuen, 2009 21 BCD APHAB, GHABP Own 4 – – + + – – – ? +
 Quality assessment: (1) randomisation; (2) concealment; (3) ethical approval; (4) prospective; (5) eligibility criteria; (6) power calculation; (7) control 
group; (8) missing data, and (9) funding source. + = Clearly present; – = clearly absent; ? = unclear. GBI = Glasgow Benefit Inventory; HHIA = Hearing 
Handicap Inventory for Adults.
1 Effect sizes could not be calculated from the data included in the study report. 2 Evidence for BCD relative to the unaided condition (pre-post) 
graded as level 4. 
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95% CI 0.45–0.66) and the largest effect for CI (mean 0.92, 95% CI 
0.61–1.24). An analysis comparing disease-specific and generic ef-
fect sizes was not conducted as the generic estimate would reflect 
data from a single study only [Arndt et al., 2011a].
 Discussion 
 This study aimed to summarise the current evidence for the ef-
fects of hearing-assistive devices on the HRQoL of adults with SSD. 
A search of five electronic databases identified 23 studies reported 
across 24 articles, the majority of which were non-experimental 
observational studies in which participants acted as their own con-
trol. The results of a mixed-effect meta-analysis suggested that 
ACD, BCD and CI all have the capacity to improve HRQoL as 
measured using disease-specific instruments. The improvements 
resulted from reductions in difficulty with understanding speech 
in BN and RV, and in determining the location of sounds.
 Only two studies measured impacts on HRQoL using generic 
instruments [Newman et al., 2008; Arndt et al., 2011a]. Generic 
approaches to measuring HRQoL seek to capture changes to health 
described in terms of a set of dimensions that have been selected 
to (a) reflect aspects of health that could limit a person’s indepen-
dence and to engage in social and vocational activities and (b) are 
relevant to a broad range of health conditions. The primary advan-
tage of generic instruments is that they permit comparisons of 
health benefits across different health services and can therefore 
inform resource allocation decisions within health care systems 
[Drummond et al., 2005].
 The data reported by Arndt et al. [2011a] demonstrate that 
CROS devices and cochlear implantation can have small effects on 
generic HRQoL when measured using the HUI3. This finding is 
compatible with previous studies which have observed that the 
HUI3 is sensitive to hearing-related interventions such as hearing 
aids [Barton et al., 2004] and CIs [UK Cochlear Implant Study 
Group, 2004] in patients with a bilateral hearing loss. The limited 
available data therefore suggest that the HUI3 is a generic measure 
that is sensitive to the effects of hearing-assistive devices on HRQoL 
in SSD. While no effect size could be computed for the SF-36 data 
reported by Newman et al. [2008], the user manual for the SF-36 
suggests that group mean scores below 47 are below average 
[Maruish, 2011]. The mean data extracted from Newman et al. 
[2008] indicated that social functioning and emotional role func-
tion were below average in adults with SSD and improved to aver-
age levels after BCD use. The results of these two studies provide 
preliminary evidence that the impact of hearing-assistive devices 
on HRQoL can be detected using generic instruments.
 A disease-specific approach to measuring HRQoL is attractive 
because the instruments are designed to be sensitive to the impact 
of the disease and to the benefits of related interventions [Bess, 
2000]. However, the output from a disease-specific instrument is 
not directly relatable to that of a generic instrument unless both 
have been developed to provide output values reflecting the prefer-
ences (‘utilities’) of a population [Abrams et al., 2005]. Disease-
specific measures of HRQoL, such as the APHAB, that profile a 
patient on one or more dimensions face the same limitation as 
disease-specific measures of function (e.g. sound localisation and 
speech perception) as they are of limited value to commissioners 
of health care services whose perspective encompasses the health 
care system as a whole rather than one aspect of it. Instead, profile 
instruments are informative in measuring clinically relevant 
changes in outcomes on scales easily interpretable by those treating 
patients with hearing loss [Chisolm et al., 2007].
–2.0 0
SMD
2.0
First author, year (outcome: dimension) SMD (95% CI)
Wazen, 2003 (APHAB: AV) –0.69 (–1.29, –0.08)
Arndt, 2011a (SSQ: Qualities) –0.25 (–0.88, 0.38)
Arndt, 2011a (SSQ: Speech) –0.16 (–0.78, 0.47)
Hol, 2010 (APHAB: AV) –0.11 (–0.70, 0.48)
Bosman, 2003 (APHAB: AV) –0.04 (–0.79, 0.70)
Niparko, 2003 (APHAB: EC) 0.05 (–0.57, 0.67)
Niparko, 2003 (APHAB: RV) 0.18 (–0.45, 0.80)
Niparko, 2003 (APHAB: BN) 0.30 (–0.33, 0.93)
Wazen, 2003 (APHAB: EC) 0.30 (–0.25, 0.86)
Arndt, 2011a (SSQ: Spatial) 0.31 (–0.32, 0.94)
Niparko, 2003 (APHAB: AV) 0.32 (–0.32, 0.95)
Bosman, 2003 (APHAB: EC) 0.32 (–0.44, 1.08)
Hol, 2010 (APHAB: EC) 0.36 (–0.25, 0.97)
Hol, 2010 (APHAB: BN) 0.43 (–0.19, 1.05)
Bosman, 2003 (APHAB: RV) 0.51 (–0.28, 1.30)
Wazen, 2003 (APHAB: BN) 0.51 (–0.06, 1.09)
Hol, 2010 (APHAB: RV) 0.60 (–0.04, 1.24)
Wazen, 2003 (APHAB: RV) 0.75 (0.13, 1.36)
Hol, 2010 (SSQ: Spatial) 0.82 (0.10, 1.54)
Bosman, 2003 (APHAB: BN) 1.00 (0.09, 1.90) Fig. 1. Effect sizes associated with the use of 
an ACD compared to the unaided condi-
tion. Effect sizes were obtained using dis-
ease-specific measures and are expressed as 
SMDs. Error bars plot 95% CIs. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ity
 o
f N
ot
tin
gh
am
   
   
   
   
   
   
   
   
   
   
 
12
8.
24
3.
39
.0
 - 
12
/9
/2
01
6 
2:
19
:1
0 
PM
 Proceedings Audiol Neurotol 2015;20(suppl 1):79–86
DOI: 10.1159/000380753
83
–1.5 1.50
SMD
3.0
First author, year (outcome: dimension) SMD (95% CI)
Oeding, 2010 (APHAB: AV) –0.49 (–1.01, 0.03)
Hol, 2010 (APHAB: AV) –0.30 (–0.91, 0.30)
Arndt, 2011a (SSQ: Qualities) –0.28 (–0.88, 0.33)
Saliba, 2011 (APHAB: AV) –0.18 (–0.61, 0.25)
House, 2010 (APHAB: AV) –0.17 (–0.49, 0.15)
Desmet, 2012 (APHAB: AV) –0.17 (–0.79, 0.46)
Arndt, 2011a (SSQ: Speech) –0.16 (–0.76, 0.43)
Moore, 2013 (APHAB: AV) –0.13 (–0.78, 0.53)
House, 2010 (SSQ: Qualities) –0.05 (–0.45, 0.34)
Hol, 2010 (APHAB: RV) –0.05 (–0.64, 0.54)
Moore, 2013 (APHAB: EC) 0.00 (–0.65, 0.65)
Moore, 2013 (APHAB: RV) 0.05 (–0.61, 0.70)
Moore, 2013 (APHAB: BN) 0.13 (–0.53, 0.78)
Desmet, 2012 (SHQ: Child) 0.18 (–0.45, 0.80)
Gluth, 2010 (APHAB: AV) 0.19 (–0.39, 0.76)
House, 2010 (SSQ: Spatial) 0.20 (–0.20, 0.60)
Arndt, 2011a (SSQ: Spatial) 0.23 (–0.37, 0.83)
House, 2010 (SSQ: Speech) 0.27 (–0.13, 0.67)
Wazen, 2003 (APHAB: AV) 0.30 (–0.25, 0.86)
Hol, 2010 (APHAB: BN) 0.30 (–0.30, 0.91)
Bosman, 2003 (APHAB: EC) 0.31 (–0.45, 1.07)
Desmet, 2012 (SHQ: Localisation) 0.34 (–0.29, 0.98)
Yuen, 2009 (APHAB: AV) 0.36 (–0.20, 0.92)
House, 2010 (APHAB: EC) 0.37 (0.04, 0.70)
Saliba, 2011 (APHAB: BN) 0.41 (–0.04, 0.85)
Niparko, 2003 (APHAB: EC) 0.42 (–0.22, 1.07)
Wazen, 2003 (APHAB: EC) 0.43 (–0.14, 0.99)
Gluth, 2010 (APHAB: EC) 0.44 (–0.16, 1.05)
Bosman, 2003 (APHAB: AV) 0.47 (–0.31, 1.25)
Saliba, 2011 (APHAB: EC) 0.47 (0.02, 0.92)
House, 2010 (APHAB: RV) 0.48 (0.14, 0.82)
Desmet, 2012 (APHAB: EC) 0.48 (–0.17, 1.14)
Desmet, 2012 (SHQ: Male) 0.51 (–0.15, 1.17)
Hol, 2010 (SSQ: Spatial) 0.52 (–0.14, 1.18)
Desmet, 2012 (SHQ: Music) 0.52 (–0.14, 1.18)
Desmet, 2012 (SHQ: Noise-C) 0.52 (–0.14, 1.18)
Desmet, 2012 (SHQ: Female) 0.54 (–0.13, 1.20)
Saliba, 2011 (APHAB: RV) 0.55 (0.09, 1.01)
Niparko, 2003 (APHAB: BN) 0.57 (–0.10, 1.24)
Oeding, 2010 (APHAB: EC) 0.61 (0.07, 1.14)
Hol, 2010 (APHAB: EC) 0.62 (–0.03, 1.26)
Oeding, 2010 (APHAB: RV) 0.69 (0.15, 1.24)
Desmet, 2012 (SHQ: Noise-L) 0.69 (0.00, 1.39)
House, 2010 (APHAB: BN) 0.70 (0.34, 1.05)
Gluth, 2010 (APHAB: BN) 0.71 (0.06, 1.37)
Gluth, 2010 (APHAB: RV) 0.72 (0.06, 1.37)
Gluth, 2010 (GHABP: Disability) 0.73 (0.18, 1.27)
Bosman, 2003 (APHAB: RV) 0.79 (–0.06, 1.64)
Niparko, 2003 (APHAB: AV) 0.80 (0.09, 1.51)
Desmet, 2012 (APHAB: BN) 0.82 (0.10, 1.54)
Niparko, 2003 (APHAB: RV) 0.84 (0.12, 1.56)
Desmet, 2012 (SHQ: Quiet) 0.85 (0.12, 1.57)
Yuen, 2009 (APHAB: EC) 0.87 (0.23, 1.51)
Desmet, 2012 (APHAB: RV) 0.88 (0.15, 1.61)
Murray, 2011 (APHAB: EC) 0.90 (0.41, 1.40)
Yuen, 2009 (APHAB: RV) 0.94 (0.29, 1.59)
Moore, 2013 (APHAB: AV) 1.00 (0.20, 1.80)
 2 
(For legend see next page.)
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 Disease-specific effect sizes were derived from within-subject 
comparisons of the aided and unaided conditions in all but one 
study [House et al., 2010]. The majority of the reported effects may 
therefore have been influenced by some form of selection bias, i.e. 
patients could have inadvertently been selected for inclusion or as-
signed a device based on factors other than their level of hearing 
loss that may not have been specified in the published report. In a 
small subset of studies, it was unclear whether the unaided condi-
tion was evaluated before or after provision of a hearing-assistive 
device. Other studies stated that the unaided condition was as-
sessed after patients had used the hearing-assistive devices for 
some time [Dumper et al., 2009]. It is possible that patients as-
sessed under these circumstances may value their unaided HRQoL 
differently than those who have no experience with the use of any 
–1.5 1.50
SMD
3.0
hearing-assistive device. Some caution should, therefore, be taken 
about generalising these results to the wider population of adult 
patients with SSD.
 The current review identified a wide range of disease-specific 
instruments that have been used to measure HRQoL when evalu-
ating the use of hearing-assistive devices for SSD in adults. Either 
the APHAB or the SSQ was used in all but one of the 23 studies. 
Both instruments include questions relating to the perception of 
speech in BN, the difficulties with listening in a range of everyday 
environments and the effort required to listen. In addition, the SSQ 
asks about difficulties with locating sounds and judging the dis-
tance of sounds. These are abilities that are reported as being par-
ticularly impaired by individuals with SSD [McLeod et al., 2008] 
and by those with an asymmetric hearing loss more generally [No-
First author, year (outcome: dimension) SMD (95% CI)
Wazen, 2003 (APHAB: RV) 1.02 (0.35, 1.69)
Wazen, 2003 (APHAB: BN) 1.03 (0.35, 1.70)
Murray, 2011 (APHAB: BN) 1.05 (0.53, 1.57)
Oeding, 2010 (APHAB: BN) 1.10 (0.48, 1.73)
Bosman, 2003 (APHAB: BN) 1.13 (0.18, 2.08)
Yuen, 2009 (APHAB: BN) 1.13 (0.44, 1.83)
Moore, 2013 (APHAB: RV) 1.17 (0.32, 2.01)
Moore, 2013 (APHAB: BN) 1.17 (0.32, 2.02)
Pai, 2012 (SSQ: Qualities) 1.19 (0.68, 1.70)
Newman, 2008 (APHAB: RV) 1.21 (0.30, 2.12)
Newman, 2008 (APHAB: EC) 1.24 (0.32, 2.16)
Pai, 2012 (SSQ: Spatial) 1.25 (0.72, 1.77)
Barbara, 2010 (GBI: General) 1.28 (0.28, 2.29)
Murray, 2011 (APHAB: RV) 1.30 (0.73, 1.87)
Moore, 2013 (APHAB: EC) 1.35 (0.45, 2.26)
Yuen, 2009 (GHABP: Disability) 1.48 (0.70, 2.27)
Newman, 2008 (APHAB: BN) 1.50 (0.49, 2.51)
Pai, 2012 (SSQ: Speech) 1.86 (1.21, 2.50) Fig. 2. Effect sizes for BCDs compared to 
the unaided condition obtained using dis-
ease-specific instruments. GBI = Glasgow 
Benefit Inventory. 
–2.0
SMD
6.02.0
First author, year (outcome: dimension) SMD (95% CI)
Arndt, 2011a (SSQ: Qualities) 0.22 (–0.38, 0.82)
Tavora-Vieira, 2013b (SSQ: Speech) 0.41 (–0.27, 1.08)
Vermeire, 2009 (SSQ: Qualities) 0.75 (0.01, 1.49)
Arndt, 2011a (SSQ: Speech) 0.90 (0.20, 1.61)
Tavora-Vieira, 2013b (SSQ: Qualities) 0.94 (0.16, 1.73)
Vermeire, 2009 (SSQ: Speech) 1.02 (0.21, 1.82)
Vermeire, 2009 (SSQ: Spatial) 1.09 (0.27, 1.92)
Arndt, 2011a (SSQ: Spatial) 1.25 (0.46, 2.04)
Tavora-Vieira, 2013b (SSQ: Spatial) 1.26 (0.39, 2.14)
Tavora-Vieira, 2013a (SSQ: Qualities) 1.27 (0.09, 2.45)
Tavora-Vieira, 2013a (SSQ: Speech) 1.38 (0.16, 2.61)
Tavora-Vieira, 2013a (SSQ: Spatial) 4.54 (1.59, 7.49)
 Fig. 3. Effect sizes for CIs compared to the 
unaided condition obtained using disease-
specific instruments. 
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ble and Gatehouse, 2004]. The SSQ was also the only instrument 
to have been used in evaluations of devices in all three categories, 
i.e. ACD, BCD and CI.
 An additional mixed-effect meta-analysis was conducted using 
SSQ data alone to determine whether the SSQ is sensitive to the 
impact of all three device categories on HRQoL. Estimated mean 
effect sizes obtained using the SSQ alone were similar to those de-
rived across all disease-specific instruments (ACD 0.17, BCD 0.49 
and CI 0.96) and SSQ data were also significantly influenced by 
device type [QM(2) = 6.21, p < 0.05]. The analysis revealed sig-
nificant effects of BCD use (95% CI 0.15–0.82) and of cochlear 
implantation (95% CI 0.58–1.33). Although the SSQ did not detect 
a statistically significant impact of ACD on HRQoL (95% CI –0.40 
to 0.73), only two studies provided SSQ data after ACD use that 
limited the power of the analysis to detect small effects. This spec-
ulative analysis suggests that the SSQ is a disease-specific measure 
that is sensitive to the impact of both CROS and restorative de-
vices, such as CIs, on HRQoL in SSD.
 The review did not identify any validated instruments specifi-
cally designed for measuring HRQoL in those with SSD. Instru-
ments such as the SSQ and the APHAB do include questions about 
many listening abilities that are impaired as a result of SSD and 
which may be aided by the use of an assistive device. However, they 
do not distinguish between sounds located on the impaired and 
non-impaired sides. The position of a sound relative to the im-
paired ear is a factor that has been found to influence the level of 
difficulty experienced by patients with SSD and which they can 
rate as more important to resolve than difficulties with under-
standing speech in noise and in localising sounds [McLeod et al., 
2008]. While the development and validation of a specific instru-
ment for measuring HRQoL in SSD would be useful to the field, 
existing instruments such as the SSQ are an appropriate choice 
when evaluating the impact of hearing-assistive devices whose pri-
mary purpose is to aid speech perception in noise and sound lo-
calisation.
 Conclusions 
 A synthesis of the current evidence for the impact of hearing-
assistive devices on HRQoL in adults with SSD suggests that, when 
measured using disease-specific instruments, the average effect of 
ACDs on HRQoL is small and BCDs have a medium effect. CIs are 
associated with a larger effect size, but one which should be con-
sidered a medium effect due to being derived from within-subject 
comparisons of HRQoL before and after implantation. The review 
identified the SSQ as a disease-specific instrument that is sensitive 
to the impact of CROS and restorative hearing-assistive devices on 
HRQoL. Few studies have measured the impact of these devices 
using generic instruments, but data from those that have suggest 
that generic instruments such as the HUI3 are sensitive to changes 
in the HRQoL of adults with SSD.
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